Eli Lilly Lawsuit Challenges CMS Coverage Standard For Alzheimer's Diagnostic
This article was originally published in The Gray Sheet
A lawsuit filed by Medicare beneficiaries with support from the manufacturer of an imaging agent approved to help evaluate adults for Alzheimer’s disease says diagnostic scans should not be required to show a change in disease management or outcomes to qualify for Medicare coverage. CMS limits coverage to the beta-amyloid plaque to use in clinical trials, and only one trial has been approved.
You may also be interested in...
Agency’s final national coverage determination for beta amyloid positron emission tomography to diagnose dementia confirms that Medicare will cover the procedure only in clinical trials. On the positive side, it may offer a bit more flexibility in trial design.
Health Canada has licensed Hugo for urologic and gynecologic laparoscopic surgical procedures.
Public Company Edition: It has been almost a month since a biopharma firm launched an IPO in the US, but special purpose acquisition corporations continue to take drug makers public, including Alvotech and Aerami. Outside the US, MaaT closed an IPO in Paris and BeiGene priced a Shanghai offering.